Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer

Bibliography

• Cortes J, O'Shaughnessy J, Loesch D, Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011;377(9769):914-23
   PubMed Web of Science ®Google Scholar
• Gennari A, Stockler M, Puntoni M, Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 2011;29(16):2144-9
   PubMed Web of Science ®Google Scholar
• Bai RL, Paull KD, Herald CL, Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 1991;266(24):15882-9
   PubMed Web of Science ®Google Scholar
• Jordan MA, Kamath K, Manna T, The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4(7):1086-95
   PubMed Web of Science ®Google Scholar
• Okouneva T, Azarenko O, Wilson L, Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 2008;7(7):2003-11
   PubMed Web of Science ®Google Scholar
• Cigler T, Vahdat LT. Eribulin mesylate for the treatment of breast cancer. Expert Opin Pharmacother 2010;11(9):1587-93
   PubMed Web of Science ®Google Scholar
• Tan AR, Rubin EH, Walton DC, Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 2009;15(12):4213-19
   PubMed Web of Science ®Google Scholar
• Witteveen P, Marchetti S, Mergui-Roelvink M, Eribulin mesylate pharmacokinetics in patients with hepatic impairment [abstract 2582]. J Clin Oncol 2010;28(Suppl):15
   PubMed Web of Science ®Google Scholar
• Goel S, Mita AC, Mita M, A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 2009;15(12):4207-12
   PubMed Web of Science ®Google Scholar
• Zhang ZY, King BM, Pelletier RD, Wong YN. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol 2008;62(4):707-16
   PubMed Web of Science ®Google Scholar
• Schwartsmann G, Da Rocha AB, Mattei J, Lopes R. Marine-derived anticancer agents in clinical trials. Expert Opin Investig Drugs 2003;12(8):1367-83
   PubMed Web of Science ®Google Scholar
• Towle MJ, Salvato KA, Budrow J, In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001;61(3):1013-21
   PubMed Web of Science ®Google Scholar
• Kuznetsov G, TenDykek U, Yu MJ. Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cell lines in vitro [abstract c58]. Proc Am Assoc Cancer Res 2007;48:275
   Google Scholar
• Swami U, Petrylak DP, Raftopoulos H, Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors [abstract 2589]. J Clin Oncol 2010;28(Suppl):15
   PubMed Web of Science ®Google Scholar
• Goel R, Chen E, Welch S, Phase I Study of E7389/gemcitabine combination in patients with advanced solid tumours [abstract e13509]. J Clin Oncol 2009;27:Suppl
   PubMed Web of Science ®Google Scholar
• Devriese A, Witteveen P, Voest EE, Eribulin dosing in patients with advanced solid tumors and hepatic impairment. ASCO General meeting. J Clin Oncol 2011;29(Suppl):abstract 2544
   Google Scholar
• Vahdat LT, Pruitt B, Fabian CJ, Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009;Jun2027(18):2954-61
   PubMed Web of Science ®Google Scholar
• Cortes J, Vahdat L, Blum JL, Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010;28(25):3922-8
   PubMed Web of Science ®Google Scholar
• Aogi K, Iwata H, Masuda N, A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol 2012;23(6):1441-8
   PubMed Web of Science ®Google Scholar
• Health USNIo. Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer. 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01527487 [Last accessed 03 May 2012]
   Google Scholar
• Health USNIo. Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer. 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01388647 [Last accessed 03 May 2012]
   Google Scholar
• Swami U, Chaudhary I, Ghalib MH, Goel S. Eribulin -- a review of preclinical and clinical studies. Crit Rev Oncol Hematol 2012;81(2):163-84
   PubMed Web of Science ®Google Scholar
• Gitlitz BJ, Tsao-Wei DD, Groshen S, A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol 2012;7(3):574-8
   PubMed Web of Science ®Google Scholar
• Hensley ML, Kravetz SJ, Jia X, Eribulin mesylate (halichondrin B analog E7389) in platinum-sensitive ovarian cancer: a phase II study, CTEP #7431 [abstract 5090]. J Clin Oncol 2011;29:Suppl
   Google Scholar
• Quinn DI, Aparicio A, Tsao-Wei DD, Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)—Final report: a California Cancer Consortium-led NCI/CTEP-sponsored trial [abstract 4539]. J Clin Oncol 2010;28(Suppl):15
   PubMed Web of Science ®Google Scholar
• Twelves C, Cortes J, Vahdat LT, Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer 2010;10(2):160-3
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803
   PubMed Web of Science ®Google Scholar